Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CorMedix (CRMD) Operating Income: 2012-2025

Historic Operating Income for CorMedix (CRMD) over the last 12 years, with Sep 2025 value amounting to $51.3 million.

  • CorMedix's Operating Income rose 1661.93% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.0 million, marking a year-over-year increase of 327.17%. This contributed to the annual value of -$22.4 million for FY2024, which is 54.34% up from last year.
  • Latest data reveals that CorMedix reported Operating Income of $51.3 million as of Q3 2025, which was up 162.73% from $19.5 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Operating Income registered a high of $51.3 million during Q3 2025, and its lowest value of -$16.7 million during Q1 2024.
  • For the 3-year period, CorMedix's Operating Income averaged around $3.5 million, with its median value being -$6.9 million (2023).
  • In the last 5 years, CorMedix's Operating Income plummeted by 56.66% in 2023 and then soared by 1,661.93% in 2025.
  • Quarterly analysis of 5 years shows CorMedix's Operating Income stood at -$7.8 million in 2021, then fell by 7.83% to -$8.4 million in 2022, then crashed by 50.35% to -$10.5 million in 2023, then soared by 68.59% to $12.9 million in 2024, then spiked by 1,661.93% to $51.3 million in 2025.
  • Its Operating Income was $51.3 million in Q3 2025, compared to $19.5 million in Q2 2025 and $20.1 million in Q1 2025.